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Poster presentations
TMR5 (ZedupexTM) is a product of a Kenyan medicinal plant, pre-
pared as a lyophilized extract and a cream. The products have been 
evaluated for preclinical safety and efficacy in suitable in vitro and in 
vivo systems of herpes infections. Herpes is a viral infection affect-
ing over 60% of the sub-Saharan Africa young adult population. It is 
caused by two similar viruses, HSV-1 and HSV-2 which share 50% 
gene sequence homology. The infection in a major cause of genital 
ulcer disease, associated with increased risks of HIV acquisition and 
transmission. The aim is to develop TMR5 as an alternative anti-
herpes agent, this being necessitated by increased resistance to 
available drugs and the cost of the drug of choice, acyclovir, in the 
region. Using the trypan blue exclusion test, plaque inhibition and 
viral yield reduction assays for assessment of cytotoxicity (CC50) 
and efficacy (EC50), and Mice and guinea pig cutaneous and genital 
HSV infection models respectively following oral and topical treat-
ments, TMR5 exhibited no cytotoxicity in mammalian cell lines 
with a wide therapeutic index (CC50 ≥ 58.5 ± 4.6µg/ml). An EC50 of 
≤ 14.7 ± 3.7µg/ml for both wild type and resistant strains of HSV 
was realised in plaque and viral yield assays. Oral (250 mg/kg) and 
topical (10% cream) administrations exhibited significant delay in 
onset of infections, hindered progression of infection to lethal forms 
with increased mean survival times and low mortality in both mice 
and guinea pig models. No acute toxicity has been realised at the 
therapeutic concentrations. TMR5 has demonstrated a high poten-
tial as an anti-herpes agent and arrangements are presently under-
way to evaluate its efficacy and safety in human clinical trials. A 
pilot production scheme supported by the National Commission for 
Science, Technology and Innovation (NCSTI) of Kenya has been 
undertaken as means of developing TMR5 as an alternative man-
agement therapy for herpes infections.
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Background Aim of the study was to determine the IL-4, IL-10 
and TNF-α profiles in plasma of north-eastern Ukrainian HIV-1 
infected individuals with different CD4 T-cell levels.
Methods We used a immunoassay method to measure IL-4, IL-10, 
TNF-α in plasma of 118 HIV-1 infected people among whom there 
were 80 (67.8%) men and 38 (32.2%) women aged (32.61 ± 0.87) 
years. Patients were divided into groups depending on the levels of 
CD4 T lymphocytes. Group I included 52 people with T-helper cell 
counts ≥ 350 cells/µL, group II - 66 patients with T-helper cell 
counts ≤ 200 cells/µL. Comparison group consisted of 30 normal 
healthy individuals.
Results In the cytokine profile of HIV-1 infected people the 
increased levels of pro-inflammatory cytokine TNF-α compared to 
controls (group I - (0.77 ± 0.08), group II - (2.34 ± 0.69), healthy 
controls - (0.51 ± 0.32) pg/mL, p < 0.05) and the anti-inflammatory 
IL-10 (group I - (3.99 ± 0.99), group II - (20.08 ± 0.44), healthy con-
trols - (1.68 ± 0.32) pg/mL, p < 0.001) were demonstrated. No sig-
nificant difference in IL-4 between surveyed troops and comparison 
group was found.
Patients with CD4 T lymphocyte levels ≤ 200 cells/µL showed 
significantly higher plasma concentration of TNF-α and IL-10 com-
pared with the group I (p < 0.05). Among HIV-1 infected from 
group II mean serum concentrations of TNF-α higher than that of 
group I in 3 times (p < 0.05). A significant increase in the concentra-
tion of IL-10 detected in patients with severe immunodeficiency 
(IL-10 levels in group II was 5 times higher, p < 0.05), which may 
indirectly indicate a more active involvement of IL-10 during dis-
ease progression.
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Conclusion HIV-1 infection was associated with an increase in 
levels of TNF-α and IL-10. Immune imbalance due to changes in 
concentrations of cytokines is more pronounced in HIV-infected 
individuals with severe immunosuppression with CD4 T lympho-
cyte counts ≤ 200 cells/µL.
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Background Little information exists about penile squamous cell 
carcinoma (PSCC), penile carcinoma in situ (PCIS) and male genital 
lichen sclerosus (MGLSc) in HIV.
Methods A retrospective review of case notes was performed on 
HIV-positive men who had presented to specialised Male Genital 
Dermatoses Clinics between May 2011 and February 2013.
Results 39 men were identified. The mean age at diagnosis was 48 
years (range 26 – 71 years). The mean diagnostic delay was 20 
months (range 1 – 72 months). 35 were uncircumcised at presenta-
tion (4 were circumcised at birth/childhood). The majority of the 
cases had PCIS (21); 8 had MGLSc, 2 had lichen planus (GLP), 2 had 
PSCC and the remaining cases had more than one diagnosis (1 had 
PSCC and MGLSc, 2 had PSCC and PCIS, 3 had PCIS and MGLSc); 
6 men had co-existing anal dysplasia (2 had anal SCC); 36 were on 
ARVs. All genital dermatoses were treated according to our conven-
tional practise. The majority (31) is in remission; 6 have residual 
disease and receive ongoing treatment (1 GLP, 1 MGLSc and 4 PCIS); 
2 have been lost to follow-up; most (32) have been circumcised 
(including 4 circumcised at birth/childhood). 1 has a short foreskin 
hence circumcision is not indicated.
Conclusion Advances in ARV treatment have improved the sur-
vival of individuals with HIV. This has led to increased interest in 
long-term morbidities, including cancer. MGLSc and PCIS can prog-
ress to invasive cancer. The risk of PSCC in HIV despite ARV 
treatemnt is x5–6. The presence of the foreskin confers cancer risk. 
Uncircumcised HIV men should be counselled about the risk of 
PSCC. There may be an argument for prophylactic circumcision in 
high-risk cases such. Certainly, clinicians should enquire about the 
genital health of HIV-positive men and undertake regular (ano)
genital examination at follow-up.
cLImacTerIc symPTons and assocIaTed FacTors In 
hIV seroPosITIVe women
doi:10.1136/sextrans-2013-051184.0447
a L Valadares, J Lui- Filho, L Costa-Paiva, E Amaral, M Souza, M Souza, A M Pinto-
Neto. UNICAMP, Campinas - SP, Brazil 
Background In the menopausal transition, the occurrence of 
insomnia, genito-urinary, psychological and.vasomotor symptoms 
may occur and this may be aggravated by the diagnosis of HIV 
infection.
Methods Cross-sectional study including 273 HIV-infected and 
264 HIV uninfected Brazilian women. They were submitted to an 
interview to assess climacteric symptoms, socio-demographic char-
acteristics and weight and height measurement.
Results The average age was 47.7 ± 5.8 years in HIV seropositive 
women and 49.8 ± 5.3 years in seronegative (p < 0.001). Bivariate 
analysis showed a lower prevalence of vasomotor symptoms in the 
HIV-positive Group (p = 0.009), specifically hot flushes (p < 0.002) 
and sweating (p = 0.049). Vaginal dryness was less prevalent in HIV-
positive (p < 0.005). Depression and insomnia showed no statistical 
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